Skip to content

Study · Animal study (in vivo) · rodent · 2026

11 results

Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain.

Spanswick DC, Wei H, Zhao FY, Caldeira Borges da Cruz MP, Whyment AD, Campbell-Galland A, O'Sullivan K, Autelitano F, Guillemot M, Kenley D, Gearing AJ, Pickering AE, Imlach WL

Pain2 Jun 2026

PMID42263267 (opens in a new tab)PMCIDPMC13382871 (opens in a new tab)DOI10.1097/j.pain.0000000000004014 (opens in a new tab)PepBankPUB-42263267
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rodent neuropathic pain models, LAT8881 reversed mechanical allodynia.

    In plain wordsIn rodents with nerve injury pain, LAT8881 reversed pain from light touch.

    Peptide
    AOD-9604
    Outcome
    DecreaseMechanical allodynia in neuropathic models
    Study

    rodentn: not reported in source

    rodent neuropathic pain models (incl. chronic constriction injury)
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LAT8881 reversed mechanical allodynia in multiple rodent neuropathic models, including chronic constriction injury
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rodents with chronic constriction injury, LAT8881 suppressed spontaneous ectopic firing in vivo at the dorsal root ganglion.

    In plain wordsIn rodents with nerve injury, LAT8881 reduced abnormal spontaneous nerve firing at the dorsal root ganglion.

    Peptide
    AOD-9604
    Outcome
    DecreaseSpontaneous ectopic firing at the dorsal root ganglion
    Study

    rodentn: not reported in source

    chronic constriction injury
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    where it suppressed spontaneous ectopic firing in vivo at the dorsal root ganglion (DRG)
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rodents with chronic constriction injury, LAT8881 suppressed wind-up in the dorsal horn.

    In plain wordsIn rodents with nerve injury, LAT8881 reduced wind-up, a build-up of pain signals in the spinal cord.

    Peptide
    AOD-9604
    Outcome
    DecreaseWind-up in dorsal horn neurons
    Study

    rodentn: not reported in source

    chronic constriction injury
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    wind-up, and spontaneous activity in wide dynamic range neurons in the dorsal horn.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rodents with chronic constriction injury, LAT8881 suppressed spontaneous activity in wide dynamic range neurons in the dorsal horn.

    In plain wordsIn rodents with nerve injury, LAT8881 reduced spontaneous activity of pain-signalling neurons in the spinal cord.

    Peptide
    AOD-9604
    Outcome
    DecreaseSpontaneous activity of wide dynamic range neurons
    Study

    rodentn: not reported in source

    chronic constriction injury
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    wind-up, and spontaneous activity in wide dynamic range neurons in the dorsal horn.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rodents, LAT8881 had little effect on inflammatory hypersensitivity.

    In plain wordsIn rodents, LAT8881 had little effect on pain sensitivity caused by inflammation.

    Peptide
    AOD-9604
    Outcome
    No significant changeInflammatory hypersensitivity
    Study

    rodentn: not reported in source

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with little effect on inflammatory hypersensitivity or physiological nociception
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rodents, LAT8881 had little effect on physiological nociception.

    In plain wordsIn rodents, LAT8881 had little effect on normal pain sensing.

    Peptide
    AOD-9604
    Outcome
    No significant changePhysiological nociception
    Study

    rodentn: not reported in source

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with little effect on inflammatory hypersensitivity or physiological nociception
  7. 07AnimalAnimal study (in vivo)Mechanism

    siRNA knockdown of LanCL1 in the dorsal root ganglion blocked LAT8881 activity.

    In plain wordsIn rodents, switching down the protein LanCL1 in nerve ganglia blocked the effect of LAT8881.

    Peptide
    AOD-9604
    Outcome
    Not applicableEffect of LanCL1 knockdown on LAT8881 activity
    Study

    rodentn: not reported in source

    siRNA knockdown of LanCL1 in dorsal root ganglion
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This was validated with siRNA knockdown of LanCL1 in DRG, which blocked LAT8881 activity.
  8. 08LabEx vivo tissueMechanism

    In ex vivo spinal cords, LAT8881 induced membrane potential hyperpolarisation.

    In plain wordsIn spinal cord tissue in the lab, LAT8881 made nerve cell membranes more negatively charged (hyperpolarised).

    Peptide
    AOD-9604
    Outcome
    DecreaseMembrane potential in spinal cord neurons
    Study

    rodentn: not reported in source

    ex vivo spinal cord
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also induced membrane potential hyperpolarisation and suppressed spontaneous and primary-afferent-mediated excitatory events in ex vivo spinal cords.
  9. 09LabEx vivo tissueMechanism

    In ex vivo spinal cords, LAT8881 suppressed spontaneous excitatory events.

    In plain wordsIn spinal cord tissue in the lab, LAT8881 reduced spontaneous excitatory nerve signals.

    Peptide
    AOD-9604
    Outcome
    DecreaseSpontaneous excitatory events
    Study

    rodentn: not reported in source

    ex vivo spinal cord
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also induced membrane potential hyperpolarisation and suppressed spontaneous and primary-afferent-mediated excitatory events in ex vivo spinal cords.
  10. 10LabEx vivo tissueMechanism

    In ex vivo spinal cords, LAT8881 suppressed primary-afferent-mediated excitatory events.

    In plain wordsIn spinal cord tissue in the lab, LAT8881 reduced excitatory signals coming from pain nerve fibres.

    Peptide
    AOD-9604
    Outcome
    DecreasePrimary-afferent-mediated excitatory events
    Study

    rodentn: not reported in source

    ex vivo spinal cord
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It also induced membrane potential hyperpolarisation and suppressed spontaneous and primary-afferent-mediated excitatory events in ex vivo spinal cords.
  11. 11LabEx vivo tissueMechanism

    A photoaffinity conjugate of the active metabolite of LAT8881 pulled down LanCL1 as the binding target in the spinal cord.

    In plain wordsIn lab tests on spinal cord tissue, a labelled form of the active LAT8881 breakdown product bound to the protein LanCL1.

    Peptide
    AOD-9604
    Outcome
    Not applicableBinding target of LAT8881 active metabolite
    Study

    n: not reported in source

    spinal cord
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    To identify protein targets of LAT8881, a photoaffinity conjugate of the active metabolite was used to pull down LanCL1 as the binding target in the spinal cord.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.